Technology Strategy Board, United Kingdom   Report issue

Government Phase 2
Founded: Swindon United Kingdom (2007)

Organization Overview

First Clinical Trial
2012
NCT01541852
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

adenovirus-specific t-cells (1 trial)

hesperitin (1 trial)

losmapimod (1 trial)

resveratrol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 2)

Glucose Intolerance (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4